An Experimental Study That Investigates Effects of Atreleuton in Metabolic Syndrome

The inflammation, LDL oxidation, and insulin resistance play an important role in the development of metabolic syndrome (MetS). This study aims to investigate the effects of atreleuton on serum lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), leukotriene B4 (LTB-4), insulin, and adipose tissue glucose transporter 4 (GLUT-4) levels in an experimental MetS model in rats. The rats were randomly divided into 3 groups: Group 1 (control, n = 7); Group 2 (MetS group, n = 8), Group 3 (MetS+atreleuton administered group, atreleuton(25 mg/kg/day) was administrated orally by gavage during the last 4 weeks of the experiment). MetS was created by feeding rats with high fructose andfat diet for 10 weeks in groups 2 and 3. Measurements of test parameters were made by ELISA method. The atreleuton caused a significant decrease in levels of serum LTB-4, LOX-1, insulin, and homeostatic model assessment for insulin resistance (HOMA-IR), while significantly increase on quantitative insulin sensitivity check index (QUICKI). However, atreleuton did not cause a significant change in tissue GLUT-4 level. The results of this study suggest that atreleutonmay be a protective agent against MetS complications by decreasing the levels of LTB-4 and LOX-1 that play an important role in MetS pathogenesis. Besides, the effect of atreleuton on the tissue GLUT-4 pathway needs to be supported by further studies.

PDF

___

1. Xu H, Li X, Adams H, Kubena K, Guo S. Etiology of metabolic syndrome and dietary intervention. Int J Mol Sci 2019; 20: 128.

2. Mellen PB, Cefalu WT. Herrington DM. Diabetes, the metabolic syndrome, and angiographic progression of coronary arterial disease in postmenopausal women. Arterioscler Thromb Vasc Biol 2006; 26: 189- 193.

3. Ozturk O, Colak Y, Senates E, et al. Increased serum soluble lectin-like oxidized low-densityl ipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease World J Gastroenterol 2015; 21: 8096-8102.

4. Md Sayed AS, Zhao Z, Guo L, et al. Serum lectin-like oxidized-low density lipoprotein receptor-1 and adiponectin levels are associated with coronary artery diseases companied with metabolic syndrome. Iran Red Crescent Med J 2014; 16: 12106.

5. Klip A, McGraw TE, James DE. Thirty sweet years of GLUT-4. J Biol Chem 2019; 294: 11369-11381.

6. Leguisamo NM, Lehnen AM, Machado UF, et al. GLUT-4 content decreases along with insulin resistance and high levels of inflammatory markers in rats with metabolic syndrome. Cardiovasc Diabetol 2012; 11: 100.

7. Wan M, Tang X, Stsiapanava A, Haeggström JZ. Biosynthesis of leukotriene B4. Semin Immunol 2017; 33: 3-15.

8. Filgueiras LR, Serezani CH, Jancar S. Leukotriene B4 as a potential therapeutic target for the treatment of metabolic disorders. Front Immunol 2015; 515.

9. Back M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des. 2009, 15: 3116–32.

10. Tardif JC, L'allier PL, Ibrahim R, et al. Treatment with 5’lipooxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging 2010; 3: 298-307.

11. Calvo-Ochoa E, Hernández-Ortega K, Ferrera P, Morimoto S, Arias C. Short-term high-fatand- fructose feeding produces insulin signaling alterations accompanied by neurite and synaptic reduction and astroglial activation in the rat hippocampus. J Cereb Blood Flow Metab 2014; 1001-1008.

12. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410.

13. Wong SK, Chin KY, Suhaimi FH, Fairus A, Ima-Nirwana S. Animal models of metabolic syndrome: a review. Nutr Metab 2016; 13: 65.

14. Chakrabarti SK, Wen Y, Dobrian AD, et al.. Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats. Am J Physiol Endocrinol Metab 2011; 300: 175-187.

15. Li P, Oh DY, Bandyopadhyay G, et al. LTB-4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med 2015; 21: 239-247.

16. De Caterina R and Zampolli A. From asthma to atherosclerosis-5-lipoxygenase. leukotrienes. and inflammation. N Engl J Med 2004; 350: 47.

17. Pettersen. D, Broddefalk J, Emtenaes H, et al. Discovery and early clinical development of an inhibitor of 5-Lipoxygenase activating protein (AZD5718) for treatment of coronary artery disease. J Med Chem 2019; 62: 4312-4324.

18. Lai XF, Qin HD, Guo LL, Luo ZG, Changa J, Qin CC. Hypercholesterolemia increases the production of Leukotriene B4 in neutrophils by enhancing the nuclear localization of 5- Lipoxygenase. Cell Physiol Biochem 2014; 34: 1723-1732.

19. Gaztanaga J, Farkouh M, Rudd JH, et al. A phase 2 randomized, double-blind, placebo controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome. Atherosclerosis 2015; 240: 53-60.

20. Pothineni NVK, Karathanasis SK, Ding Z, Arulandu A, Varughese KI, Mehta JL. LOX-1 in atherosclerosis and myocardial ischemia: Biology. genetics. and modulation. J Am Coll Cardiol 2017; 69: 2759-2768.

21. Brinkley TE, Kume N, Mitsuoka H, Phares DA, Hagberg JM. Elevated soluble lectin-like oxidized LDL receptor-1 (sLOX-1) levels in obese postmenopausal women. Obesity (Silver Spring) 2008; 16: 1454-1456.

22. Puttaruk. P, Pipatsatitpong D, Siripurkpong P. Soluble lectin-like oxidized low density lipoprotein receptor-1 in metabolic syndrome. Asian Biomed (Res. Rev. News) 2015; 9: 675- 682.

23. Civelek S, Kutnu M, Uzun H, et al. Soluble lectin-like oxidized LDL receptor 1 as a possible mediator of endothelial dysfunction in patients with metabolic syndrome. J Clin Lab Anal 2015; 29: 184-190.

24. Murase T, Kume N, Kataoka H, et al. Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler Thromb Vasc Biol 2000; 20: 715-720.

25. Navarra T, Del Turco SD, Berti S, Basta G. The lectin-like oxidized low density lipoprotein receptor-1 and its soluble form: cardiovascular in applications. J Atheroscler Thromb 2010; 17: 317-331.

26. Li Q, Zhao W, Zeng X, Hao Z. Ursolic acid attenuates atherosclerosis in ApoE (−/−) mice: role of LOX-1 mediated by ROS/NFkappa B pathway. Molecules 2018; 23: 1101.

27. Dominguez JH, Mehta JL, Li D. et al. Anti- LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations. Am J Physiol Renal Physiol 2008; 294: 110-119.

28. Zayed EA, AinShoka. AA, El Shazly KA, Abd El Latif HA. Improvement of insulin resistance via increase of GLUT-4 and PPARγ in metabolic syndrome‐induced rats treated with omega‐3 fatty acid or l‐carnitine. J Biochem Mol Toxicol 2018; 32: 22218.

29. Abel ED, Peroni O, Kim JK, et al. Adiposeselective targeting of the GLUT-4 gene impairs insulin action in muscle and liver. Nature 2001; 409: 729-733.

30. Fazakerley DJ, Krycer JR, Kearney AL, Hocking SL, James DE. Muscle and adipose tissue insulin resistance: m alady without mechanism? J Lipid Res 2019; 60: 1720-1732.